Literature DB >> 32623006

Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017-2018 National Health and Nutrition Examination Survey.

Stefano Ciardullo1, Tommaso Monti2, Gianluca Perseghin3.   

Abstract

BACKGROUND & AIMS: Metabolic-associated fatty liver disease (MAFLD) is common among adolescents, but the prevalence of significant fibrosis in this age group is not known. We aimed to estimate the prevalence of MAFLD and significant (≥F2) fibrosis by transient elastography (TE) in adolescents in the United States.
METHODS: We analyzed TE data from participants 12-18 years old included in the National Health and Nutrition Examination Survey 2017-2018 (data available from 867 adolescents). Steatosis was evaluated by the median controlled attenuation parameter (CAP) and fibrosis by median liver stiffness measurement.
RESULTS: Two-hundred forty participants (24.16%; 95% CI, 21.07-27.24) had any degree of steatosis (CAP≥248 dBm), 123 participants (11.6%; 95% CI, 9.19-14.06) had S3 steatosis (CAP≥280 dBm), and 51 participants (4.4%; 95% CI, 2.51-6.33) had significant fibrosis (liver stiffness ≥7.4 kPa). Multivariate analyses revealed that body mass index (odds ratio [OR] per unit increase, 1.2; 95% CI, 1.2-1.4), sex (OR female vs male participants , 0.5; 95% CI, 0.4-0.7), ethnicity (OR, Hispanic vs non-Hispanic white, 4.5; 95% CI, 1.7-11.8), and hypertension (OR, 3.5; 95% CI, 1.3-9.9) were associated with S3 steatosis, whereas body mass index (OR, 1.1 per unit increase; 95% CI, 1.0-1.2) and ethnicity (OR, non-Hispanic black vs non-Hispanic white, 3.9; 95% CI, 1.2-13.2) were associated with significant fibrosis. High proportions of participants with fibrosis were in the normal weight category (35%) and had normal levels of alanine aminotransferase (78%).
CONCLUSIONS: Prevalence of MAFLD and significant fibrosis are alarmingly high in adolescents in the National Health and Nutrition Examination Survey 2017-2018. Levels of alanine aminotransferase and blood biomarkers do not correctly identify adolescents with more advanced disease. Effective noninvasive strategies to differentiate simple steatosis from progressive forms are urgently needed.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Population; Screening; Teen; Young Age

Year:  2020        PMID: 32623006     DOI: 10.1016/j.cgh.2020.06.048

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  12 in total

1.  Circadian Misalignment Rather Than Sleep Duration is Associated with MAFLD: A Population-Based Propensity Score-Matched Study.

Authors:  Rahul Kumar; Su Lin; Zhiyuan Weng; Weijie Ou; Jiaofeng Huang; Medha Singh; Mingfang Wang; Yueyong Zhu
Journal:  Nat Sci Sleep       Date:  2021-01-29

2.  Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018.

Authors:  Xiaotao Zhang; Natalia I Heredia; Maya Balakrishnan; Aaron P Thrift
Journal:  PLoS One       Date:  2021-06-03       Impact factor: 3.240

3.  The association between non-alcoholic fatty liver disease and serum ferritin levels in American adults.

Authors:  Naibin Yang; Yi Lu; Liwen Cao; Mingqin Lu
Journal:  J Clin Lab Anal       Date:  2022-01-07       Impact factor: 2.352

4.  Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis.

Authors:  Stefano Ciardullo; Guido Grassi; Giuseppe Mancia; Gianluca Perseghin
Journal:  Eur J Gastroenterol Hepatol       Date:  2022-04-01       Impact factor: 2.566

5.  Non-Invasive Diagnostic Test for Advanced Fibrosis in Adolescents With Non-Alcoholic Fatty Liver Disease.

Authors:  Antonella Mosca; Luca Della Volpe; Anna Alisi; Silvio Veraldi; Paola Francalanci; Giuseppe Maggiore
Journal:  Front Pediatr       Date:  2022-04-26       Impact factor: 3.418

6.  Value of the triglyceride glucose index combined with body mass index in identifying non-alcoholic fatty liver disease in patients with type 2 diabetes.

Authors:  Nong Li; Huiwen Tan; Aixia Xie; Cheng Li; Xuan Fu; Weiting Xang; Amina Kirim; Xuefang Huang
Journal:  BMC Endocr Disord       Date:  2022-04-15       Impact factor: 2.763

Review 7.  MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.

Authors:  Takumi Kawaguchi; Tsubasa Tsutsumi; Dan Nakano; Mohammed Eslam; Jacob George; Takuji Torimura
Journal:  Clin Mol Hepatol       Date:  2021-11-10

8.  Prospective assessment of liver stiffness by shear wave elastography in childhood obesity: a pilot study.

Authors:  Domenico Corica; Antonio Bottari; Tommaso Aversa; Letteria Anna Morabito; Selenia Curatola; Angela Alibrandi; Giorgio Ascenti; Malgorzata Wasniewska
Journal:  Endocrine       Date:  2021-07-23       Impact factor: 3.633

9.  Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis.

Authors:  Lu Pan; Pan Huang; Xia Xie; Jiachen Xu; Dawei Guo; Yuan Jiang
Journal:  Dig Liver Dis       Date:  2020-09-17       Impact factor: 4.088

10.  Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population.

Authors:  Stefano Ciardullo; Rosa Cannistraci; Simone Mazzetti; Andrea Mortara; Gianluca Perseghin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-26       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.